How pharmacy dispensing fees work

Ohio's Medicaid program asked every one of its 2,802 enrolled pharmacies in 2024 what it cost them to fill a prescription. Usable answers came back from 2,262. Weighted by Medicaid volume, the median cost was $9.38 per prescription, according to the state's November 2024 cost-of-dispensing report⁷, and the gap between small and large stores was wide. Leaving out specialty pharmacies, those filling fewer than 50,000 prescriptions a year averaged $15.85, while those filling 100,000 or more averaged $9.86.

Ohio pays its smallest pharmacies a $15.47 dispensing fee and its largest $8.30, per CMS's state-by-state reimbursement table⁶ for the quarter ending September 2026.

That fee is the second half of every Medicaid prescription payment. The first half covers the drug. For cheap generics the second half is now usually the larger one, so how fees are set has become one of the main facts about pharmacy pay. Medicare drug plans and commercial insurers set theirs a different way, and the gap between the two systems is large.

What the fee is supposed to cover

Federal Medicaid rules define a professional dispensing fee as one that "pays for costs in excess of the ingredient cost of a covered outpatient drug each time a covered outpatient drug is dispensed," in the words of 42 CFR 447.502¹. The listed costs include a pharmacist's time checking a patient's coverage, drug utilization review, measuring or mixing, filling the container, counseling, handing over the prescription, delivery, special packaging and the overhead of running the store. The state's own administrative costs are excluded.

The word "professional" dates to 2016. It arrived with the Covered Outpatient Drugs final rule published Feb. 1, 2016. In a February 2016 letter to state Medicaid directors⁵, CMS said the new wording was meant to reinforce its position that the fee should reflect the pharmacist's professional services and costs, while adding that it would not mandate a formula.

The same rule changed how the drug half is paid. Under 42 CFR 447.512², for drugs without a federal upper limit, a state's payments may not exceed, in the aggregate, the lower of actual acquisition cost plus the state's professional dispensing fee or the pharmacy's usual and customary charge to the public. Drugs with a federal upper limit face a separate cap. CMS's letter gave states until April 1, 2017, to have plan amendments in effect. Our explainer on how Medicaid pays for generics covers the ingredient side.

How states arrive at a number

A state cannot simply pick a fee. When it proposes to change either half of pharmacy payment, 42 CFR 447.518(d)³ requires it to consider both and to submit "adequate cost-based data, such as a State or national survey of retail pharmacy providers." The rule adds that market-based research, such as what pharmacies accept from other insurers, does not qualify as support for the fee.

In practice states rely on a cost-of-dispensing survey. Pharmacies report labor and overhead costs along with prescription counts. An accounting contractor allocates store-wide expenses to the prescription department, leaves out items such as advertising, bad debts and income taxes, and divides by the number of prescriptions. The four recent state reports below were all prepared for state Medicaid agencies, and each reports results weighted by Medicaid prescription volume.

Figures include specialty pharmacies and are inflated to a common midpoint (June 30, 2024, for Ohio, Virginia and Nebraska; December 31, 2023, for Oregon). Fees are from CMS's September 2026 table⁶.

Weighting matters. Ohio's unweighted mean was $43.10, pulled up by a few specialty pharmacies handling infusion and clotting-factor products; excluding them, it was $12.33. Ohio's report also said its broad cost measures rose roughly 10 to 16 percent since the prior survey, with labor and overhead both contributing, after years in which the consultant had seen little to no increase.

What states pay now

CMS's September 2026 compilation shows how differently states turn those surveys into fees. In about two dozen states the standard retail fee sits between $10 and $11: $10.64 in Alabama, $10.92 in New Jersey, $10.18 in New York, $10.65 in Virginia. Rhode Island and Puerto Rico pay $8.96. Illinois pays $8.85 to most pharmacies and $15.55 to designated critical access pharmacies.

Several states tier by volume because, as the Ohio report⁷ puts it, prescription volume and cost per prescription have been inversely correlated in every survey its authors have performed. Montana pays $17.52 to pharmacies filling fewer than 40,000 prescriptions a year and $12.83 above 70,000. Washington's tiers run from $14.30 to $9.80, Wisconsin's from $15.69 to $10.51, and Tennessee pays $13.16 or $9.02 depending on whether a store fills fewer than 65,000 claims. Alaska sets separate fees by location and pharmacy type, up to $26.81 for tribal health pharmacies.

Ohio's authors noted the tradeoff. A single statewide fee, which most states use, is simpler to run; tiers match fees more closely to an individual pharmacy's costs but add administrative work.

Medicare drug plans handle fees differently

Medicare Part D has its own definition. 42 CFR 423.100⁴ describes dispensing fees in terms close to Medicaid's, covering pharmacist time, filling the container, staff salaries and the cost of maintaining the pharmacy. But no state survey sets the number. Each plan sponsor, usually through a pharmacy benefit manager, negotiates it with pharmacies, and the same regulation folds dispensing fees into the plan's "negotiated price" for a drug.

Those negotiated fees tend to be small. In an April 2024 presentation on generic pricing in Part D¹¹, Medicare Payment Advisory Commission staff said dispensing fees are typically a fixed dollar amount, giving $1 as an example, so they make up a larger share of the price of low-cost drugs. The same slides note that since Jan. 1, 2024, the pharmacy's payment at the point of sale must reflect the lowest amount it may receive, including fees pharmacies used to pay back to plans after the sale. Our pieces on how Part D pays for generics and how pharmacies get paid go further into those contracts.

Why the fee now outweighs the drug

As generic ingredient costs have fallen, the fee has become most of the payment. At October 2026 rates in the NADAC survey¹², 30 generic lisinopril 10 mg tablets cost a pharmacy about 54 cents and 30 amlodipine 5 mg tablets about 31 cents. Against a $10.65 Virginia Medicaid fee, the drug is about 5 percent of the payment for lisinopril and 3 percent for amlodipine. A $1 fee of the kind MedPAC staff described would leave the pharmacy depending mostly on what the plan pays for the ingredient.

Fees are one input in the economics of chain and independent stores, which our pharmacy count analysis tracks. The fee appears in our glossary, and our long-deflation analysis shows how far ingredient costs have dropped.

Surveys come around on a schedule. Virginia's January 2025 report⁹ says its next cost-of-dispensing survey is due in 2029, and it urged the state to require pharmacy participation before then, noting that some chain organizations take part only when required.